Know Cancer

or
forgot password

A Comparison of 2 Schedules of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy - A Randomized Phase III Trial


Phase 3
18 Years
N/A
Not Enrolling
Male
Prostatic Neoplasms

Thank you

Trial Information

A Comparison of 2 Schedules of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy - A Randomized Phase III Trial


Inclusion Criteria:



- Eligible to receive prostate brachytherapy as per the Ontario Provincial Guidelines
will be eligible for this study (i.e. prostate specific antigen [PSA] < 10, Gleason
score <7, Stage <= T2a)

Exclusion Criteria:

- Patients already taking anti-inflammatory drugs

- Patients with allergic-type reactions, including asthma and urticaria, to aspirin or
nonsteroidal anti-inflammatory agents (see product information)

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To compare 2 schedules of MeloxicamTM given in the peri-operative period to reduce prostate swelling after permanent seed implantation for prostate cancer

Principal Investigator

Juanita Crook, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Princess Margaret Hospital, Canada

Authority:

Canada: Ethics Review Committee

Study ID:

UHN REB 03-0840-C

NCT ID:

NCT00152919

Start Date:

February 2004

Completion Date:

May 2009

Related Keywords:

  • Prostatic Neoplasms
  • Neoplasms
  • Prostatic Neoplasms

Name

Location